Myriad Genetics + Gateway Genomics – Supporting women on their pregnancy journey November 1, 2022 By: Melissa Gonzales - President, Women’s Health, Myriad Genetics When the big moment comes and parents learn they are having a baby, life chan... Continue Reading
Can a genetic test improve prostate cancer treatment decisions? A patient story. October 25, 2022 https://myriad-1.wistia.com/medias/w9go8af7h5 How can a prognostic test inform care plans for a patient with prostate cancer? Richard Tyus and his uro... Continue Reading
Carrier Screening is for Everyone September 13, 2022 Achieving equity in healthcare is a major motivator for the Myriad Genetics team. We believe that genetic testing and screening, done right, can help address s... Continue Reading
Equitable Carrier Screening Strategies Provide Better Prenatal Risk-Detection for All Patients September 9, 2022 By: Dr. Haywood Brown As providers who specialize in the care of pregnant patients, our goals are to help foster patient understanding of maternal and... Continue Reading
Maternal Health Is in Crisis. We Need to Change That Right Now. August 29, 2022 By Melissa Gonzales, president of Women's Health According to the World Health Organization, the U.S. is one of the most dangerous places in the world for a... Continue Reading
Myriad Genetics is committed to being your partner of choice August 5, 2022 Against the backdrop of recent shifts in the genetic testing industry, we would like to take a minute to reiterate Myriad Genetics’ determination to bring cl... Continue Reading
Understanding Prolaris test results June 17, 2022 After a prostate cancer diagnosis, choosing an appropriate treatment path can be incredibly stressful for you and your loved ones. Further complicating the pro... Continue Reading
What is the Prolaris test? June 10, 2022 The Prolaris test is a genetic test for untreated men with prostate cancer that can determine how quickly cancer is growing. Prolaris helps provide clarity abo... Continue Reading
The Next Wave of the Pandemic May 18, 2022 When the Covid-19 pandemic first hit, many patients took what they thought would be a temporary break from preventive care visits to the doctor. However, mor... Continue Reading
New Guidelines from AUA and ASTRO Support Inclusion of Genomic Testing in Localized Prostate Cancer May 17, 2022 By Thomas Slavin, M.D., chief medical officer, Myriad Genetics According to the American Cancer Society, in 2022 more than 268,000 men in the United S... Continue Reading
Making Genetic Testing More Inclusive May 12, 2022 Myriad Genetics’ innovative approach to genetic testing gives more women the information they need to stay healthy. By FastCo Works For the past 30 yea... Continue Reading
The Future of Genetic Testing: How a Love of DNA Led to More Comprehensive Tests April 23, 2022 For more than 30 years now, scientists at Myriad Genetics have been finding creative ways to coax new information out of human genes. The love for exploring th... Continue Reading
Genetic insights for more actionable and personalized prostate cancer March 25, 2022 Connect with us The AUA National meeting is centered around the exploration of the latest and groundbreaking advancements in urology, and th... Continue Reading
New Enhancements to Noninvasive Prenatal Screening (NIPS) March 21, 2022 Myriad Genetics was honored to participate in one of the most important conferences for Maternal Fetal Medicine specialists and other medical providers focused... Continue Reading
Inside One of the World’s Most Innovative Companies March 8, 2022 In March 2022, Myriad Genetics was named one of the World’s Most Innovative Companies by Fast Company. Since 2008, Fast Company’s Most Innovative Comp... Continue Reading